![iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology](https://www.thelancet.com/cms/attachment/15d21829-04ae-41e4-adce-3c0180239598/gr1_lrg.jpg)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
![Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000146/F3.large.jpg)
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
![PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study](https://i1.rgstatic.net/publication/346649757_RECIST_and_iRECIST_criteria_for_the_evaluation_of_nivolumab_plus_ipilimumab_in_patients_with_microsatellite_instability-highmismatch_repair-deficient_metastatic_colorectal_cancer_The_GERCOR_NIPICOL_ph/links/5fd7467d92851c13fe850315/largepreview.png)
PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study
![iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology](https://www.thelancet.com/cms/attachment/8bc5d1e3-404b-4692-af38-4907b9da6686/gr2_lrg.jpg)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
![Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000146/F1.large.jpg)
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
![PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis](https://www.researchgate.net/publication/339530728/figure/tbl1/AS:863168620425224@1582806844715/Food-and-Drug-Administration-calculated-ORR-and-DOR-by-iRECIST-and-RECIST-V11-by_Q320.jpg)
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
![Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho, Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,](https://journals.sagepub.com/cms/10.1177/0284185119887588/asset/images/large/10.1177_0284185119887588-fig5.jpeg)
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
![PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis](https://www.researchgate.net/publication/339530728/figure/tbl2/AS:863168620425225@1582806844747/Concordance-in-best-overall-response-achieved-prior-to-use-of-non-protocol-specified_Q320.jpg)
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
![PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis](https://i1.rgstatic.net/publication/348172229_Comparison_of_RECIST_11_and_iRECIST_in_Patients_Treated_with_Immune_Checkpoint_Inhibitors_A_Systematic_Review_and_Meta-Analysis/links/6026b1ac92851c4ed56a8f1e/largepreview.png)